PARP Inhibition During Pre-surgical Window in Breast/Ovary Cancer

Inclusion Criteria

• •All patients must have cytology/ biopsy proven diagnosis of a mullerian carcinoma, high clinical index of suspicion for ovarian cancer OR triple negative, BRCA mutated breast cancer.
• •Patients may not have received prior treatment for breast or ovarian cancer.
• •All patients must be of at least 18 years of age.
• •ECOG Performance status must be 0,1 or 2.
• •Patients must not have received a prior PARP inhibitor
• •Adequate organ and marrow function as defined below:
• •absolute neutrophil count \>/= 1500/mcL
• •Platelets \> /= 100,000 /mcl
• •Hemoglobin \>/= 8 g/dl
• •Total bilirubin \</= 1.5 x the institutional ULN
• •AST, ALT \</= 3 x the institutional ULN
• •Creatinine \</= the institutional ULN
• •Women of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry, for the duration of study participation, and for 90 days following completion of therapy. Should a woman become pregnant or suspect she is pregnant while participating in this study, she should inform her treating physician immediately.
• •A female of child-bearing potential is any woman (regardless of sexual orientation, having undergone a tubal ligation, or remaining celibate by choice) who meets the following criteria:
• •* Has not undergone a hysterectomy or bilateral oophorectomy; or
• •* Has not been naturally postmenopausal for at least 12 consecutive months (i.e., has had menses at any time in the preceding 12 consecutive months).
• •Patients must be able to swallow and retain oral medications.
• •Ability to understand and the willingness to sign a written informed consent.